Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar

Aim to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care.

Author Image

By: Charlie Sternberg

Associate Editor

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate—marking the second agreement between the two companies and reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.   The global agreement to develop an additio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters